Compare LIVE & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIVE | NSRX |
|---|---|---|
| Founded | 1968 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 36.9M |
| IPO Year | 1998 | N/A |
| Metric | LIVE | NSRX |
|---|---|---|
| Price | $10.30 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 6.1K | ★ 41.8K |
| Earning Date | 05-14-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 158.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.03 | $1.98 |
| 52 Week High | $25.42 | $9.99 |
| Indicator | LIVE | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 50.63 |
| Support Level | $10.25 | $2.78 |
| Resistance Level | $14.26 | $3.58 |
| Average True Range (ATR) | 0.62 | 0.27 |
| MACD | 0.16 | -0.00 |
| Stochastic Oscillator | 68.64 | 32.17 |
Live Ventures Inc is a holding company of diversified businesses. It acquires and operates companies with a history of earnings power across five segments: Retail-Entertainment, Retail-Flooring, Flooring Manufacturing, Steel Manufacturing, and Corporate & Other. Retail-Entertainment offers new and pre-owned movies, video games, music, books, comics and collectibles through an integrated buy-sell-trade model. Retail-Flooring is a retailer and installer of flooring, carpeting, and countertops, serving consumers, builders, and contractors. Flooring Manufacturing produces and distributes carpet and hard-surface flooring. Steel Manufacturing engages in steel production and fabrication, generating the majority of revenue. Corporate & Other covers corporate costs and legacy products and services.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.